Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 1
2011 3
2012 2
2013 2
2014 2
2015 2
2017 2
2018 3
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A, Bocci G, Fallahi P, La Motta C, Ferrari SM, Mancusi C, Fioravanti A, Di Desidero T, Sartini S, Corti A, Piaggi S, Materazzi G, Spinelli C, Fontanini G, Danesi R, Da Settimo F, Miccoli P. Antonelli A, et al. J Clin Endocrinol Metab. 2014 Apr;99(4):E572-81. doi: 10.1210/jc.2013-2321. Epub 2014 Jan 1. J Clin Endocrinol Metab. 2014. PMID: 24423321
Targeting histone deacetylase in thyroid cancer.
Russo D, Durante C, Bulotta S, Puppin C, Puxeddu E, Filetti S, Damante G. Russo D, et al. Expert Opin Ther Targets. 2013 Feb;17(2):179-93. doi: 10.1517/14728222.2013.740013. Epub 2012 Dec 13. Expert Opin Ther Targets. 2013. PMID: 23234477 Review.
Rational combinations using HDAC inhibitors.
Bots M, Johnstone RW. Bots M, et al. Clin Cancer Res. 2009 Jun 15;15(12):3970-7. doi: 10.1158/1078-0432.CCR-08-2786. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509171 Review.
17 results